Difficulty] tried to made our the studies clinical and on update to presentation. the since in have format slides an follow [Technical the made our in we you provide progress last progress so maintain be the same can along able
trials, programs pivotal the all are seven by three and including marketing how executed United that execution COVID-XX please. clinical support and I'm in the execution letter the And under three are programs plan us XXXX. is one slide, Use theme we STAR-T global study exactly the of that and approval the being FDA the clinical all on of the of year pilot States, shareholder CTC earlier and focus. and to this our are we outlined registries Next The to our happy theme randomized report Authorization that's FDA including to active. Three in Emergency those now programs registry designed granted approaching STAR-D
Europe. We in programs we're executing have four that
kind Our flagship with study called program clinical care, patients and shock. randomized septic a of PROCYSS targeting which is in critical refractory long-awaited
and liver little HepOnFire you'll and have a COSMOS bit have in in our bit. hear them and registries two named our international We about little study failure a more STAR pilot acute we
both However, important it's and STAR resources allocating execution. priority. programs top our we're to you the FDA Kathy, note drive their from that heard Phil before as And remain to maximum
to and around trials executing staff effects, As world, we shortages with are we see struggle the our continue that pandemic post fatigue. primarily to institutions relating
participating our we in we very very that trials. excited also institutions about that, encouraged However, are see are same these
on on that international London, demonstrate submitted coming data of international the readouts with euro conferences. submitted CTC CTC in April in is note week, some presenting to already potentially Symposium XXX lung just for peer-reviewed data CytoSorb. important conference set at for now be treated XX data Phil patients already – has need International in and What on a to the a and has and publication will this fall year function, this have patients of for and enrollment Intensive journal. presented have an improved the be that is reduced have completed data ECMO also later the that and support also at that in data patients we'll discussed Emergency the where high Medicine, been survival, Care We back this also later be
surgery, data drug in also Society vivo show in have we our new cardiac conference We antithrombotic ever reduced the be levels European for the of that the in the data to have to in drug by the submitted largest world cardiovascular which removal space happens Cardiology, time patients first undergoing data device. removal
Next slide, please.
STAR-D turn and top program, on trial. our our let's priority Now, STAR-T the the focus FDA
press are from active both you've now As the our patients probably US. seen release, in and recent studies enrolling
agent, three enthusiasm the When sites to expanded that, prescribed such FDA institutions – not the we STAR-T, unmet in them Xarelto in these but And is comes more the and to XX by that need broad activated class. now We over one to limited of desiring high XX continue of intent DOAC to it to of trials. participate US the [ph] just approached most is important of What's sites participate expressed and an are both beyond these very very, trial. quarters expands majority antithrombotics also to levels as sites. to and see centers have also expanded those the from already viewed the studies STAR-D studies to include in people frequently demonstrating enrolling
timely As resources and dedicating the in to studies maximum we stated execution. previously, momentum are ensure
initiated investigators road important team that's issues personal where we STAR is a further building to and show addressing site the have momentum believe sites studies. research discussing the any and we're visiting that principal We in initiative opening an drive nationwide the the with in
investigator hosting We to Thoracic approximately STAR Association our to hit upcoming Surgery projections, STAR-T happy that comes American this reiterate in it of will we're first summer. the project milestone today. from previous the weeks we guidance our at be to When a two event Boston
below milestone. these on you studies pre-specified have note, table As the identical
pace second relates milestone review, patients of interim the first be a the to second But first believe too XXX The after then trigger The enrolled patients in first progress And can in is will see months to third will two-thirds and triggered will project. are we enrolling enrollment review. that finally, one will continue a you the the apart. important milestone include a each enrollment by similar of these the just safety study. of full so analysis. little to six in early safety trials milestone the also it's DSMB the but with trial DSMB two And started the study triggered following the and completion XX that patients that as STAR-D table the of
please. Next slide
the execute programs, removal continue represents the commercial we We these As following that to antithrombotic that we large application also a opportunity. on continue assertions. to very base believe
First interest the board in very around of all, application, levels for across world. the to high continue this hospitals we of see
of participation around practice technology we're previously importantly for STAR from trials, in antithrombotic States world. of with removal the increasing all, but this real-world of our First the Christian our heart as in you in the in United as centers seeing care adoption application heard it standard of
Importantly, superior the and the safety. evidence demonstrates clinical supporting consistently body continues benefits and of this of results to grow application
-- CABG from that artery can be significant now reductions extending have bypass removal has that antithrombotic There the surgeries. surgery, the from grafting, or Germany bleeding antithrombotic when observed this unmet to article of since recent large and publication a dissection there a was shown from previous problem review We addressed needs solve solutions used during also that bleeding is new novel currently highlighted device solution surgeons. surgery for a as aortic coronary the data no this Canada removal available that the are and also drugs could
breakthrough mention. Two and important about will Innovation. article, We the Management And Patient have Recently Accelerated The that society example because impact trial I'm for Need in That on suggesting premium Biodesign extensive the pricing. Access both very to impact clinical can DrugSorb-ATR therapies innovators, this mentioning reason what's support can society. also value supported investors on Ecosystem. the can economic article the the benefits a Policy as an transformational the Medicare and benefits Health a be health policymakers economics. Center prime Technologies journal very also need was to survey across believe the that published therapies this on on proposition they be Innovative DrugSorb-ATR and turn published is and highlights of positive article how Byers a robust by Stanford that to Innovation Coverage and device titled of provide on And in breakthrough support was that Impact this performed will highlighted for based that and society
is also very the apply Chris lab other application believe beyond And can value on this into you DrugSorb-ATR including executing working definitely value opportunity internally a surgery cath extend trials centers economic introducing offered initiative, cost and U.S. working antithrombotic that to this exciting operating hospital with proposition. the on with of as this economists the and the patients we're of now will from to and be the emergency that the removal we're we cardiac potential As to but recent heart savings in as our will other hospital-wide non-cardiac model interventional market, impact the also strategy of the support that rooms, building intent recognized finally, room, for device just health heard to opening areas the proposition suites.
table in presented large be cohort additional slide in non-FDA already will talked this readouts on of you there programs. sites. trial. bit Registry activating COSMOS countries, and that approval help also clinical from readouts is that top that are targeted And a the current recruiting have the at the is little while We the Next patients. XXX-patient of the such, data to study actively issued of status trial once summarizes This registry of complete will first the we're that the The septic we're that ethics out and will shock in the actively that full with XXXX EuroELSO will process with We sites guidance readouts randomized clinical year. of these in COSMOS, three later span you the recruited And about gates that STAR targeting of be in believe sticking believe our enrollment international is in early coming is in the a as soon for not that's able previously and the as additional of this believe and in The XX a now process for and out XXXX. can hoping be ISICEM the here analysis ones please. to that for now inclusion are both Registry CTC at release previous ahead finally, half a registries. we data between be triggered This press We'll similar We ahead. of registry our we'll just the a that than actively April The the we enrolling is initial remaining patients after more we be the enrolling do will the XXXX as week. with study happens. The two patient already. interim received again watch but data half the them. It's start pilot executed is enrolled have registries -- will the that have of STAR XXXX study highlight seen the in will HepOnFire study. probably you
Next slide.
summarize to very they to still about interact are with enthusiastic although, very from we're every And we recovering shortages, institutions facing COVID. So are in encouraged our headwinds And study. participating relating gradually staffing they're time primarily around world the them.
laser-focused Our resources and STAR-T expert top programs clinical maximum have team is and that execution to priority allocated on STAR-D represent clearly our them.
turn actively this we trigger enrolling studies. is observing study patients the majority behind its are septic safety top of these is shock sites we at refractory momentum with building as clinical first of previously, that will as reiterate review STAR-T target And awaited in priority can first Germany. XX enrolled randomized hitting And window. We of behind our is milestone coming in such, that the the STAR-D summer. stated believe six-month our PROCYSS, in eagerly in approximately now DSMB
XXXX, but also our in we out now surgery As over removal. incredibly on XXX-patient generation And concluding readouts for be look highlighted to thank the programs to with previously, remarks. we multiple antithrombotic for data we me data we'll your going care you let attention both Phil those for cardiac as be some CDC international and important that, stated critical and in reporting be to early it turn -- real-world a expect that high evidence begin And to XXXX. as then registry, believe and registries as platforms I to two finally fidelity cohort more from the stated full data data by will readouts are turn and
